BACTROBAN NASAL OINTMENT DIN 02236776
Status: Cancelled Pre Market
Holder: GLAXOSMITHKLINE INC
Health Canada record
| Active ingredient(s) | MUPIROCIN (MUPIROCIN CALCIUM) 2 % |
|---|
| Dosage form | Ointment |
|---|
| Route | Nasal |
|---|
| Schedule | NON-PRESCRIPTION DRUGS |
|---|
| Class | Human |
|---|
| ATC | D06AX09 MUPIROCIN |
|---|
| Original market date | |
|---|
| Current status date | 25-Oct-2017 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
GlaxoSmithKline Inc. — licence 100630, currently licensed, last inspection rating C (2025-09-15).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing MUPIROCIN (MUPIROCIN CALCIUM)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02483459 | STRAMUCIN | GLENMARK PHARMACEUTICALS CANADA INC. | Cream | MUPIROCIN (MUPIROCIN CALCIUM) 2 % | Marketed |
| 02239757 | BACTROBAN CREAM | GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC | Cream | MUPIROCIN (MUPIROCIN CALCIUM) 2 % | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 2421 | 2001-08-09 | New Drug Submission (NDS) | CHANGE IN MANUFACTURER NAME |
| 3965 | 1997-11-03 | Supplement to a New Drug Submission (SNDS) | NEW ROUTE OF ADMINISTRATION AND NEW INDICATION |
Request a quote for BACTROBAN NASAL OINTMENT
How to read a Canadian DIN record